Harvey F. Lodish is a Professor of Biology and Professor of Biological Engineering at the Massachusetts Institute of Technology and Founding Member of the Whitehead Institute for Biomedical Research. He is a Member of the National Academy of Sciences, a Fellow of the American Association for the Advancement of Science, a Fellow of the American Academy of Arts and Sciences, an Associate (Foreign) Member of the European Molecular Biology Organization, and previously served as President of the American Society for Cell Biology.
Dr. Lodish has received multiple mentoring and lifetime achievement awards, including the 2010 Mentoring Award from the American Society of Hematology, the 2016 American Society for Cell Biology WICB Sandra K. Masur Senior Leadership Mentoring Award, the 2020 Metcalf Lifetime Achievement Award from the International Society for Experimental Hematology, and the 2021 Coulter Award for Lifetime Achievement in Hematology from the American Society of Hematology.
He is the lead author of the widely used textbook Molecular Cell Biology, which has been translated into 14 languages, with the ninth edition published in January, 2021.
Dr. Lodish is a member of the Board of Trustees of Boston Children’s Hospital, and was previously Chair of the Scientific Advisory Board of the Massachusetts Life Sciences Center, the group charged with oversight of the state’s 10 year, $1 billion investment in the life sciences.
He has been a founder and scientific advisory board member of 12 biotech companies, including Genzyme (acquired by Sanofi for US$20 billion in 2011), Millennium Pharmaceuticals (acquired by Takeda for US$8.8 billion in 2008), and Rubius Therapeutics (IPO in 2018).
He holds an A.B. degree Summa Cum Laude in chemistry and mathematics from Kenyon College and a Ph.D. in genetics from the Rockefeller University.
